Journal Watch · Frontiers in Immunology · 2026
The LVI Component Hypothesis: the lymphatic-to-vascular invasion ratio as an enrichment biomarker for therapy with PD-L1×VEGF-A bispecific antibodies.
If validated, the LVR might help to select those patients most likely to respond, raising the response rate among those treated and possibly sparing those unlikely to benefit.
TL;DR
If validated, the LVR might help to select those patients most likely to respond, raising the response rate among those treated and possibly sparing those unlikely to benefit.
Key findings
- Angiogenically, blood vessel invasion reflects a VEGF-A-driven, disordered, T-cell-excluding vasculature.
- The author proposes the LVI Component Hypothesis, which is that tumor cell intravasation into lymphatic versus blood vessels can be expressed as a ratio, the lymphatic-to-vascular invasion ratio (LVR).
- This ratio may predict benefit from PD-L1×VEGF-A bispecific antibodies.
- No clinical data currently link the LVR to response, so it is presented as a hypothesis to be tested, first in archived tissue from completed trials of PD-L1×VEGF-A bispecific antibodies and then in prospective randomized trials.
- If validated, the LVR might help to select those patients most likely to respond, raising the response rate among those treated and possibly sparing those unlikely to benefit.
What they did
Bispecific antibodies with functional arms against immunologic and vascular targets are a recent class of biologics that simultaneously engage the malignant immunologic and angiogenic components of a tumor. In this setting, deconstructing LVI into its invasive lymphatic and vascular components, and expressing their ratio, is hypothesized to add predictive capability to this histologic finding. LVI-positive tumors are enriched for parameters relevant to both arms of this class of bispecific antibodies. Immunologically, they carry higher tumor mutational burden, more frequent PD-L1 expression, and TGF-β signaling.
Full abstract (original)
Background: Lymphovascular invasion (LVI) describes intravasated tumor cells within intratumoral lymphatic or blood vessels. LVI is reported routinely on pathologic examination because it is prognostic for reduced disease-free and overall survival across many solid tumors. In contrast, it is not considered a predictive biomarker because its presence cannot discriminate which patients benefit from a given therapy. To become predictive, a biomarker must reflect the aberrant, specific biology a drug targets.
What they did: Bispecific antibodies with functional arms against immunologic and vascular targets are a recent class of biologics that simultaneously engage the malignant immunologic and angiogenic components of a tumor. In this setting, deconstructing LVI into its invasive lymphatic and vascular components, and expressing their ratio, is hypothesized to add predictive capability to this histologic finding. LVI-positive tumors are enriched for parameters relevant to both arms of this class of bispecific antibodies. Immunologically, they carry higher tumor mutational burden, more frequent PD-L1 expression, and TGF-β signaling.
Results & conclusions: Angiogenically, blood vessel invasion reflects a VEGF-A-driven, disordered, T-cell-excluding vasculature. The author proposes the LVI Component Hypothesis, which is that tumor cell intravasation into lymphatic versus blood vessels can be expressed as a ratio, the lymphatic-to-vascular invasion ratio (LVR). This ratio may predict benefit from PD-L1×VEGF-A bispecific antibodies. No clinical data currently link the LVR to response, so it is presented as a hypothesis to be tested, first in archived tissue from completed trials of PD-L1×VEGF-A bispecific antibodies and then in prospective randomized trials. If validated, the LVR might help to select those patients most likely to respond, raising the response rate among those treated and possibly sparing those unlikely to benefit.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1878891 · PubMed 42666451.
Why it matters for pharma & biotech
- Directly relevant to teams in antibody / ADC therapeutics, targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: antibody / ADC therapeutics · targeted oncology / immuno-oncology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
If validated, the LVR might help to select those patients most likely to respond, raising the response rate among those treated and possibly sparing those unlikely to benefit.
What type of study is this?
It is a randomised / controlled clinical trial, published in Frontiers in Immunology in 2026. Bispecific antibodies with functional arms against immunologic and vascular targets are a recent class of biologics that simultaneously engage the malignant immunologic and angiogenic components of a tumor.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1878891. PubMed ID: 42666451. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-lvi-component-hypothesis-the-lymphatic-to-vascular-invasion-ratio-as-878891/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides